Brief: Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052
24/02/2026 12:18
Feb 24 (Reuters) - Aclaris Therapeutics Inc ACRS.O: ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH ASTHMA WITH ITS NOVEL BISPECIFIC ANTI-TSLP/IL-4RΑ ANTIBODY ATI-052 ACLARIS THERAPEUTICS INC - TOP LINE RESULTS EXPECTED IN SECOND HALF OF 2026 ACLARIS THERAPEUTICS INC - PHASE 2B PROGRAM ENCOMPASSING ASTHMA AND ATOPIC DERMATITIS EXPECTED TO START IN H2 2026 Source text: ID:nGNX5Ywq8Y Further company coverage: ACRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics Q1 net loss widens on higher R&D spending
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations